Evidence map›Paper›PMID 28672011›Full record

ArticlePloS one2017

Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Rheun-Chuan Lee, Yi-Hsiang Huang, Fa-Yauh Lee, Ming-Chih Hou, Ya-Ju Tsai and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Impact of Child Pugh B Stage for the Treatment of Advanced HCC.Journal of hepatocellular carcinoma · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. An ALBI- and Ascites-Based Model to Predict Survival for BCLC Stage B Hepatocellular Carcinoma.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  17. Review
  18. [Value of ALBI grade on precised estimation liver reserve function of patients with hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shu-Yein HoDepartment of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Po-Hong LiuDepartment of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Chia-Yang HsuFaculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.
Cheng-Yuan HsiaFaculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.
Yun-Hsuan LeeDepartment of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Rheun-Chuan LeeFaculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.
Yi-Hsiang HuangDepartment of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Fa-Yauh LeeDepartment of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Ming-Chih HouDepartment of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Ya-Ju TsaiRenown Regional Medical Center, Reno, Nevada, United States of America.
Teh-Ia HuoDepartment of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.ORCID http://orcid.org/0000-0003-2202-521X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVarious noninvasive liver reserve markers were proposed to indicate the severity of liver damage. However, the role and feasibility of these markers to predict the prognosis of patients with hepatocellular carcinoma (HCC) are unknown. We aimed to identify the prognostic role of the 8 currently used hepatic reserve markers in patients with HCC undergoing transarterial chemoembolization (TACE).

methodsBetween 2002 and 2013, a total of 881 patients with HCC undergoing TACE were prospectively identified and retrospectively analyzed. The baseline characteristics, tumor status and noninvasive markers were collected. Homogeneity and corrected Akaike information criteria (AICc) were compared between these markers. The Cox proportional hazards model was used to identify independent predictors of survival.

resultsSignificant differences in survival distribution were found for albumin-bilirubin (ALBI) grade, Child-Turcotte-Pugh (CTP) class, Lok index, fibrosis index based on 4 factors (FIB-4), Göteborg University cirrhosis index (GUCI), cirrhosis discriminant index (CDI) and model for end-stage liver disease (MELD) score (all p values <0.05). Among these markers, the ALBI grade showed the highest homogeneity and lowest AICc value, indicating a better prognostic performance. Cox multivariate analysis confirmed that ALBI grade 2, ascites, serum alkaline phosphatase and α-fetoprotein level, tumor diameter, vascular invasion and performance status were significant independent prognostic predictors. The distribution of the ALBI score well correlated with baseline CTP and MLED scores.

conclusionsOur data suggest that among the currently used liver reserve markers, ALBI grade may serve as an objective and feasible surrogate to predict the prognosis of HCC patients undergoing TACE.

Indexed as

Chemoembolization, TherapeuticAgedCarcinoma, HepatocellularFemaleHumansLiver NeoplasmsMaleMiddle AgedPrognosis

Identifiers

PMID28672011
PMCPMC5495392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.